References
- Amidon GL, Lennernas H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–20
- Arora P, Mukherjee B. (2002). Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J Pharm Sci 91:2076–89
- Barakat NS. (2006). Etodolac-liquid-filled dispersion into hard gelatin capsules: an approach to improve dissolution and stability of etodolac formulation. Drug Dev Ind Pharm 32:865–76
- Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13:123–33
- Dennis AB, Farr SJ, Kellaway W, et al. (1990). In vivo evaluation of rapid release and sustained release Gelucire capsule formulations. Int J Pharm 65:85–100
- El Massik MA, Abdallah OY, Galal S, Daabis NA. (2003). Semisolid matrix filled capsules: an approach to improve dissolution stability of phenytoin sodium formulation. Drug Dev Ind Pharm 29:531–43
- FDA Guidance for Industry. (Sept 1997). SUPAC-MR – modified release solid oral dosage forms: scale-up and post approval changes. Rockville, MD: Center for Drug Evaluation and Research (CDER)
- Fini A, Moyano JR, Ginés JM, et al. (2005). Diclofenac salts, II. Solid dispersions in PEG6000 and Gelucire 50/13. Eur J Pharm Biopharm 60:99–111
- Galal S, El Massik M, Abdallah O, Daabis N. (2003). Formulation of fast release glibenclamide liquid and semi solid matrix filled capsules. Acta Pharm 53:57–64
- Galal S, El Massik MA, Abdallah OY, Daabis NA. (2004). Study of in-vitro release characteristics of carbamazepine extended release semi solid matrix filled capsules based on gelucire. Drug Dev Ind Pharm 30:817–29
- Gonzalez E, De La Cruz C, De Nicolás R, et al. (1994). Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 41:171–8
- Hauss DJ. (2007). Oral lipid-based formulations. Adv Drug Deliv Rev 59:667–76
- Khan KA. (1975). The concept of dissolution efficiency. J Pharm Pharmacol 27:48–9
- Manjanna KM, Pramod Kumar TM, Shivakumar B. (2009). Effect of manufacturing conditions on physico-chemical characteristics and drug release profiles of aceclofenac sodium microbeads. Drug Invention Today 1:98–107
- Mutalik S, Naha A, Usha AN, et al. (2007). Preparation, in vitro, preclinical and clinical evaluations of once daily sustained release tablets of aceclofenac. Arch Pharm Res 30:222–34
- Panusa A, Selmin F, Rossoni G, et al. (2011). Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. J Pharm Sci 100:4580–6
- Soni T, Nagda C, Gandhi T, Chotai NP. (2008). Development of discriminating method for dissolution of aceclofenac marketed formulations. Dissolution Technologies 15:31–5
- Stegemann S, Bornem C. (1999). Hard gelatin capsules today – and tomorrow. Capsugel Library 1:1–23
- US FDA Guidance for Industry. (August 2000). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Rockville, MD: Center for Drug Evaluation and Research (CDER)
- Winter CA, Risley EA, Nuss GW. (1962). Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc Soc Exp Biol Med 111:544–7
- Wu CY, Benet LZ. (2005). Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11–23
- Yüksela N, Karataşa A, Özkanb Y, et al. (2003). Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation. Eur J Pharm Biopharm 56:453–9